Goldman Sachs Maintains Sell on Ginkgo Bioworks Holdings, Lowers Price Target to $1.1
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a Sell rating on Ginkgo Bioworks Holdings (NYSE:DNA) and reduced the price target from $1.25 to $1.1.
January 22, 2024 | 12:43 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs maintains a Sell rating on Ginkgo Bioworks Holdings and lowers the price target to $1.1.
The reduction in price target by a major financial institution like Goldman Sachs typically indicates a bearish outlook on the stock, suggesting a potential decrease in its market price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100